Amlodipine Besylate

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 37, Issue , 2012, Pages 31-77

  Ananchenko, Gennady ^a   Novakovic, Jasmina ^a   Lewis, Johnathan ^a  

^a Apotex Inc   (Canada)

Author keywords

ADME; Amlodipine besylate; Calcium channel blocker; Chemical properties; Pharmacodynamics; Pharmacokinetics; Physical properties; Preparation

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; ATORVASTATIN; AZIDE; CYTOCHROME P450 3A4; LACTOSE; MALEIC ACID; NITROGEN; OCTANOL; OLMESARTAN; OXYGEN; PHTHALIMIDE DERIVATIVE; SULFUR; UK 48340 26; UNCLASSIFIED DRUG; WATER;

AROMATIZATION; ARTICLE; CARDIOVASCULAR RISK; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; CYCLIZATION; DIELS ALDER REACTION; DIFFERENTIAL SCANNING CALORIMETRY; DISSOCIATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG IMPURITY; DRUG INDICATION; DRUG NOMENCLATURE; DRUG OXIDATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DYSLIPIDEMIA; ELECTROSPRAY MASS SPECTROMETRY; ENANTIOMER; ENANTIOSELECTIVITY; EUROPE; FOOD DRUG INTERACTION; GLYCATION; GRAPEFRUIT JUICE; HEATING; HUMAN; HYPERTENSION; INFRARED SPECTROMETRY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; MELTING POINT; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PROTON TRANSPORT; RECOMMENDED DRUG DOSE; REDUCTION; SOLID; STABLE ANGINA PECTORIS; STEADY STATE; TABLET; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET SPECTROSCOPY; UNITED STATES; WATER CONTENT; WATER LOSS; WATER TRANSPORT; WETTABILITY; X RAY POWDER DIFFRACTION;

EID: 84863401406     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397220-0.00002-7     Document Type: Chapter

References (98)

1. The Merck Index, an Encyclopedia of Chemicals, Drugs, and Biologicals 2006, Merck & Co., Inc, Whitehouse Station, NJ, monograph 491, p. 83. 14th ed.
2. Goldmann S., Stoltefuss J., Born L. Determination of the absolute configuration of the active amlodipine enantiomer as (-)-(S): a correction. J. Med. Chem. 1992, 35:3341-3344.
3. Thacker H.P. S-amlodipine-the 2007 clinical review. J. Indian Med. Assoc. 2007, 105:180-190.
4. Moffat A.C., Osselton M.D., Widdop B., Watts J. Clarke's analysis of drugs and poisons 2011, Pharmaceutical Press, London, Chicago, vol. 2, pp. 889-890. Fourth ed.
5. Caron G., Ermondi G., Damiano A., Novaroli L., Tsinman O., Ruell J.A., Avdeef A. Ionization, lipophilicity, and molecular modeling to investigate permeability and other biological properties of amlodipine. Bioorg. Med. Chem. 2004, 12:6107-6118.
6. Koradia V., Lopez de Diego H., Frydenvang K., Ringkjøbing-Elema M., Müllertz A., Bond A.D., Rantanen J. Solid forms of amlodipine besylate: physicochemical, structural, and thermodynamic characterization. Cryst. Growth Des. 2010, 10:5279-5290.
7. Jiang Y., Fang L., Niu X., Ma R., He Z. The effect of ion pairing on the skin permeation of amlodipine. Pharmazie 2008, 63:356-360.
8. Franke U., Munk A., Wiese M. Ionization constants and distribution coefficients of phenothiazines and calcium channel antagonists determined by a pH-Metric method and correlation with calculated partition coefficients. J. Pharm. Sci. 1999, 88:89-95.
9. Austin R.P., Davis A.M., Manners C.N. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J. Pharm. Sci. 1995, 84:1180-1183.
10. S.Y. Jang, S. Kim, S. Yun, H.J. Bang, H.K. Kim, K.H. Suh, US2010/0099884.
11. Y.-S. Chung, M.-C. Ha, WO2004/024689.
12. Lukša J., Josić D.j., Podobnik B., Furlan B., Kremser M. Semi-preparative chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine. J. Chromatogr. B 1997, 693:367-375.
13. R.J.M. Rohini, A.J.M. Ramesh, K.G.M. Mukund, US6608206, 2003.
14. Gotrane D.M., Deshmukh R.D., Ranade P.V., Sonawane S.P., Bhaval B., Gharpure M.M., Gurjar M.K. A novel method for resolution of amlodipine. Org. Proc. Res. Dev. 2010, 14:640-643.
15. G.J.B. Ettema, H. Hoorn, J.M. Lemmens, US2003139455.
16. Z. Ham, B. Furlan, A. Copar, U. Urleb, WO03/101965.
17. Rollinger J.M., Burger A. Physico-chemical characterization of hydrated and anhydrous crystal forms of amlodipine besylate. J. Therm. Anal. Calorim. 2002, 68:361-372.
18. Koradia V., de Lemos A.F.F., Allesø M., de Diego H.L., Ringljøbing-Elema M., Müllertz A., Rantanen J. Phase transformations of amlodipine besylate solid forms. J. Pharm. Sci. 2011, 100:2896-2910.
19. Lee H.W., Shin S.J., Yu H., Kang S.K., Yoo C.L. A novel chiral resolving reagent, bis((S)-mandelic acid)-3-nitrophthalate, for amlodipine racemate resolution: scalable synthesis and resolution process. Org. Proc. Res. Dev. 2009, 13:1382-1386.
20. Szabó L., Chiş V., Pîrnâ A., Leopold N., Cozar O., Orosz Sz. Spectroscopic and theoretical study of amlodipine besylate. J. Mol. Struct. 2009, 924-926:385-392.
21. 13 C CP MAS NMR and DFT study of vascular-selective drugs felodipine and amlodipine. Chem. Phys. Lett. 2008, 463:195-200.
22. Furlan B., Grdadolnik S.G., Hočevar S., Kocjan D., Levec J., Maskill H., Navrátilová H., Pospíšil J., Potáček M., Urleb U., Žmitek J. Amlodipine benzenesulfonate: a mechanistic investigation of its industrial preparation via detritylation of N-tritylamlodipine and related NMR studies. Croat. Chem. Acta 2009, 82:299-309.
23. Gibbons J., Pugh J., Dimopoulos-Italiano G., Pike R. A qualitative study of amlodipine and its related compounds by electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20:1715-1723.
24. Yasuda T., Tanaka M., Iba K. Quantitative determination of amlodipine in serum by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J. Mass Spectrom. 1996, 31:879-884.
25. Ragno G., Garofalo A., Vetuschi C. Photodegradation monitoring of amlodipine by derivative spectrophotometry. J. Pharm. Biomed. Anal. 2002, 27:19-24.
26. Yeung P.K.F., Mosher S.J., Pollak P.T. Liquid chromatography assay for amlodipine: chemical stability and pharmacokinetics in rabbits. J. Pharm. Biomed. Anal. 1991, 9:565-571.
27. Sadana G.S., Ghogare A.B. Quantitative proton magnetic resonance spectroscopic determination of nifedipine and its photodecomposition products from pharmaceutical preparation. J. Pharm. Sci. 1991, 80:895-898.
28. Abdoh A., Al-Omari M.M., Badwan A.A., Jaber A.M.Y. Amlodipine besylate-excipients interaction in solid dosage form. Pharm. Dev. Technol. 2004, 9:15-24.
29. Siva Lakshmi Devi A., Srinivasa Rao Y., Satish M., Jyothi G., Babu Rao K., Omdutt T. Structure elucidation of thermal degradation products of amlodipine. Magn. Reson. Chem. 2007, 45:688-691.
30. Arrowsmith J.E., Campbell S.F., Cross P.E., Stubbs J.K., Burges R.A., Gardiner D.G., Blackburn K.J. Long-acting dihydropyridine calcium antagonists. 1,2-Alkoxymethyl derivatives incorporating basic substituents. J. Med. Chem. 1986, 29:1696-1702.
31. Pan C., Liu F., Motto M. Identification of pharmaceutical impurities in formulated dosage forms. J. Pharm. Sci. 2011, 100:1228-1259.
32. Campbell S.F., Cross P.E., Stubbs J.K. 1983, EP 0089167.
33. Davison M.E., Wells J.I. 1989, US 4879303.
34. Kim S.-C., Choi K.-M., Cheong C.-S. Synthesis of amlodipine using Aza Diels-Alder reaction. Bull. Kor. Chem. Soc. 2002, 23:143-144.
35. Lee Y.A., Kim S.-C. Synthesis of 1,4-dihydropyridine using microwave-assisted aza-Diels-Alder reaction and its application to Amlodipine. J. Ind. Eng. Chem. 2011, 17:401-403.
36. Amlodipine Besylate, U.S. Pharmacopeia-National Formularly, USP34/NF29, The United States Pharmacopoeial Convention, 2010, pp. 1872-1873.
37. Amlodypine Besilate, European Pharmacopoeia 7.0, Council of Europe, 2010, pp. 1379-1380.
38. Amlodipine Besylate Tablets, Second Supplement to the U.S. Pharmacopeia-National Formulary, USP34/NF29, The United States Pharmacopoeial Convention, 2011, pp. 5379-5380.
39. Beresford A.P., Macrae P.V., Stopher D.A., Wood B.A. Analysis of amlodipine in human plasma by gas chromatography. J. Chromatogr. 1987, 420:178-183.
40. Beresford A.P., Macrae P.V., Alker D., Kobylecki R.J. Biotransformation of amlodipine. Identification and synthesis of metabolites found in rat, dog and human urine/confirmation of structures by gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. Arzneimittelforschung 1989, 39:201-209.
41. Scharpf F., Riedel K.D., Laufen H., Leitold M. Enantioselective gas chromatographic assay with electron-capture detection for amlodipine in biological samples. J. Chromatogr. B 1994, 655:225-233.
42. Monkman S.C., Ellis J.C., Cholerton S., Thomason J.M., Seymour R.A., Idle J.R. Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid. J. Chromatogr. B 1996, 678:360-364.
43. Mauer H.H., Arlt J.W. Screening procedure for detection of dihydropyridine calcium channel blocker metabolites in urine as part of a systematic toxicological analysis procedure for acidic compounds by gas chromatography-mass spectrometry after extractive methylation. J. Anal. Toxicol. 1999, 23:73-80.
44. Shimooka K., Sawada Y., Tatematsu H. Analysis of amlodipine in serum by a sensitive high-performance liquid chromatographic method with amperometric detection. J. Pharm. Biomed. Anal. 1989, 7:1267-1272.
45. Josefsson M., Zackrisson A.L., Norlander B. Sensitive high-performance liquid chromatographic analysis of amlodipine in human plasma with amperometric detection and a single-step solid-phase sample preparation. J. Chromatogr. B 1995, 672:310-313.
46. Josefsson M., Norlander B. Coupled-column chromatography on a chiral-AGP phase for determination of amlodipine enantiomers in human plasma: an HPLC assay with electrochemical detection. J. Pharm. Biomed. Anal. 1996, 15:267-277.
47. Carvalho M., Oliviera C.H., Mendes G.D., Sucupira M., Moraes M.E., De Nucci G. Amlodipine bioequivalence study: quantification by liquid chromatography coupled to tandem mass spectrometry. Biopharm. Drug Dispos. 2001, 22:383-390.
48. Streel B., Lainé C., Zimmer C., Sibenaler R., Ceccato A. Enantiomeric determination of amlodipine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J. Biochem. Biophys. Methods 2002, 54:357-368.
49. Klinkenberg R., Streel B., Ceccato A. Development and validation of a liquid chromatographic method for the determination of amlodipine residues on manufacturing equipment surfaces. J. Pharm. Biomed. Anal. 2003, 2:345-352.
50. Raman N.V.V.S.S., Ratnakar Reddy K., Prasad A.V.S.S., Ramakrishna K. Development and validation of RP-HPLC method for the determination of genotoxic alkyl benzenesulfonates in amlodipine besylate. J. Pharm. Biomed. Anal. 2008, 48:227-230.
51. Kasawar G.B., Farooqui M.N. Simultaneous determination of amlodipine besylate and benazepril hydrochloride in pharmaceutical dosage form by LC. Anal. Sci. 2009, 25:1495-1498.
52. Pandya K.L., Satia M., Gandhi T.P., Modi I.A., Modi R.I., Chakravarthy B.K. Detection and determination of total amlodipine by high-performance thin-layer chromatography: a useful technique for pharmacokinetic studies. J. Chromatogr. B 1995, 667:315-320.
53. Argekar A.P., Powar S.G. Simultaneous determination of atenolol and amlodipine in tablets by high-performance thin-layer chromatography. J. Pharm. Biomed. Anal. 2000, 21:1137-1142.
54. Kamble A.Y., Mahadik M.V., Khatal L.D., Dhaneshwar S.R. Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation. Anal. Lett. 2010, 43:251-258.
55. Ramadan N.S., Mohamed H.M., Moustafa A.A. Rapid and highly sensitive HPLC and TLC methods for quantitation of amlodipine besilate and valsartan in bulk powder and in pharmaceutical dosage forms and in human plasma. Anal. Lett. 2010, 43:570-581.
56. Rozhnova S.A., Gavrilin M.V., Senchenko S.P., Krikova A.B. Use of capillary electrophoresis in studies of the pharmacokinetics of amlodipine besylate. Pharm. Chem. J. 2007, 41:444-446.
57. Fakhari A.R., Nojavan S., Haghgoo S., Mohammadi A. Development of a stability-indicating CE assay for the determination of amlodipine enantiomers in commercial tablets. Electrophoresis 2008, 29:4583-4592.
58. Nojavan S., Fakhari A.R. Electro membrane extraction combined with capillary electrophoresis for the determination of amlodipine enantiomers in biological samples. J. Sep. Sci. 2010, 33:3231-3238.
59. Alnaijar A.O. Validation of a capillary electrophoresis method for the simultaneous determination of amlodipine besylate and valsartan in pharmaceuticals and human plasma. J. AOAC Int. 2011, 94:498-502.
60. Sridhar K., Sastry C.S.P., Reddy M.N., Sankar D.G., Srinivas K.R. Spectrophotometric determination of amlodipine besylate in pure forms and tablets. Anal. Lett. 1997, 30:121-133.
61. Rahman N., Azmi S.N.H. Spectrophotometric determination of amlodipine besylate by charge transfer complex formation with p-chloranilic acid. Anal. Sci. 2000, 16:1353-1356.
62. Rahman N., Azmi S.N.H. Spectrophotometric method for the determination of amlodipine besylate with ninhydrin in drug formulations. Farmaco 2001, 56:731-735.
63. Basavaiah K., Chandrashekar U., Prameela H.C. Sensitive spectrophotometric determination of amlodipine and felodipine using iron(III) and ferricyanide. Farmaco 2003, 58:141-148.
64. Rahman N., Nasrul Hoda M. Validated spectrophotometric methods for the determination of amlodipine besylate in drug formulations using 2,3-dichloro 5,6-dicyano 1,4-benzoquinone and ascorbic acid. J. Pharm. Biomed. Anal. 2003, 31:381-392.
65. Abdel-Wasood H.M., Mohamed N.A., Mahmoud A.M. Validated spectrofluorometric methods for determination of amlodipine besylate in tablets. Spectrochim. Acta A 2008, 70:564-570.
66. Ali A., Pasha K., Raju S.A., Ahmed A. Visible spectrophotometric determination of amlodipine in pharmaceutical formulation and bulk drug by using bromophenol blue. Int. J. Pharmacol. Pharm. Sci. 2010, 2:128-129.
67. Jain N., Jain R., Jain A., Pandey S.P., Jain D.K. Spectrophotometric method development and validation for quantitative estimation of amlodipine besylate in bulk drug and their dosage forms by using hydrotropic agent. Eurasian J. Anal. Chem. 2010, 5:212-217.
68. Kawase M., Saito T., Ogawa M., Uejima H., Hatsuda Y., Kawanishi S., Hirotani Y., Myotoku M., Ikeda K., Konishi H., Iga I., Yamakawa J., Nishizawa S., Yamamoto K., Tani M. Application of terahertz absorption spectroscopy to evaluation of aging variation of medicine. Anal. Sci. 2011, 27:209-212.
69. Altiokka G., Ak-Dougrukol D., Tuncel M., Aboul-Enein H.Y. Determination of amlodipine in pharmaceutical formulations by differential-pulse voltammetry with a glassy carbon electrode. Arch. Pharm. 2002, 335:104-108.
70. Gazy A.A.A. Determination of amlodipine besylate by adsorptive square-wave anodic stripping voltammetry on glassy carbon electrode in tablets and biological fluids. Talanta 2004, 62:575-582.
71. Dogan-Topal B., Bozal B., Demircigil B.T., Uslu B., Ozkan S.A. Electroanalytical studies and simultaneous determination of amlodipine besylate and atorvastatine calcium in binary mixtures using first derivative of the ratio-voltammetric methods. Electroanalysis 2009, 21:2427-2439.
72. Goyal R.N., Bishnoi S. Voltammetric determination of amlodipine besylate in human urine and pharmaceuticals. Bioelectrochemistry 2010, 79:234-240.
73. Matalka K., Arafat T., El-Thaher T., Qawasmeh K., Shebli S., Hamd M., Badwan A. Pharmacokinetic and pharmacodynamic profiles of two brands of amlodipine determined by enzyme linked immunosorbent assay. Pharm. Pharmacol. Commun 2000, 6:539-544.
74. Matalka K., El-Tharer T., Saleem M., Arafat T., Jehanli A., Baldwan A. Enzyme linked immunosorbent assay for determination of amlodipine in plasma. J. Clin. Labor. Anal. 2001, 15:47-53.
75. Meredith P.A., Elliott H.L. Clinical pharmacokinetics of amlodipine. Clin. Pharmacokin. 1992, 22:22-31.
76. Faulkner J.K., McGibney D., Chasseaud L.F., Perry J.L., Taulor I.W. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br. J. Clin. Pharmacol. 1986, 22:21-25.
77. Abernthy D.R. The pharmacokinetic profile of amlodipine. Am. Heart J. 1989, 118(5, Pt. 2):1100-1103.
78. Williams D.M., Cubeddu L.X. Amlodipine pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 1988, 28:990-994.
79. Elliott H.L., Green S.T., Vincent J., Meredith P.A. An assessment of the pharmacokinetics and pharmacodynamics of single doses of amlodipine in elderly normotensives. Pharmacol. Res. 1992, 26:33-39.
80. Laufen H., Leitold M.A. Enantioselective disposition of oral amlodipine in healthy volunteers. Chirality 1994, 6:531-536.
81. Maddi S., Yamsani M.R., Seeling A., Scriba G.K.E. Stereoselective plasma protein binding of amlodipine. Chirality 2010, 22:262-266.
82. Beresford A.P., McGibney D., Humphrey M.J., Macrae P.V., Stopfer D.A. Metabolism and kinetics of amlodipine in man. Xenobiotica 1988, 18:245-254.
83. Beresford A.P., Macrae P.V., Stopher D.A. Metabolism of amlodipine in the rat and the dog: a species difference. Xenobiotica 1988, 18:169-182.
84. Suchanova B., Sispera L., Wsol V. Liquid chromatography-tandem mass spectrometry in chiral study of amlodipine biotransformation in rat hepatocytes. Anal. Chim. Acta 2006, 573-574:273-283.
85. Stopher D.A., Beresford A.P., Macrae P.V., Humphrey M.J. The metabolism and pharmacokinetics of amlodipine in humans and animals. J. Cadiovasc. Pharmacol. 1988, 12(Suppl. 7):S55-S59.
86. Burges R.A. Amlodipine: a once daily calcium antagonist. J. Hum. Hyperten. 1991, 5(Suppl. 1):49-54.
87. Walker D.K., Humphrey M.J., Smith D.A. Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. Xenobiotica 1994, 24:243-250.
88. Josefsson M., Zackrisson A.L., Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. 1996, 51:189-193.
89. Bailey D.G., Dresser G.K. Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs 2004, 4:281-297.
90. Nakagawa K., Goto T. Effects of ingestion of grapefruit juice or grapefruit on the hypotensive effect and plasma concentrations of dihydropyridine calcium antagonists (amlodipine and nifedipine): a case study. Clin. Exp. Hypertens. 2010, 32:71-75.
91. Chung M., Garza D., Gaffney M., Glue P. Bioavailability of amlodipine besylate following oral administration as a tablet dispersed in applesauce. J. Clin. Pharmacol. 2005, 45:695-698.
92. Bompadre S., Capone P., Cingolani M.L., Ferrante L., Leone L., Ripa S. Amlodipine pharmacokinetics in hypertensive patients. Pharmacol. Res. 1990, 22(Suppl. 2):59.
93. Kungys G., Naujoks H., Wanner C. Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. Eur. J. Clin. Pharmacol. 2003, 59:291-295.
94. Flynn J.T., Nahata M.C., Mahan J.D., Portman R.J. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J. Clin. Pharmacol. 2006, 46:905-916.
95. Bhad P., Ayalasomayajula S., Karan R., Leon S., Riviere G.J., Sunkara G., Jarugula V. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. J. Clin. Pharmacol. 2011, 51:933-942.
96. Rohatagi S., Lee J., Shenouda M., Haworth S., Bathala M.S., Allison M., Rubets I., Heyrman R., Noveck R., Salazar D.E. Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J. Clin. Pharmacol. 2008, 48:1309-1322.
97. Preston R.A., Harvey P., Herfert O., Dykstra G., Jukema J.W., Sun F., Gillen D. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. J. Clin. Pharmacol. 2007, 47:1555-1569.
98. Deeks E.D. Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension. Drugs 2011, 71:209-220.